Serum Institute of India's (SII) Covovax may get approval as heterologous booster

The government may decide on allowing Serum Institute of India’s (SII) Covovax as a heterologous booster dose, meaning it can be used for people who have taken either Covishield or Covaxin for primary vaccination against Covid-19. Sources said a meeting of the subject expert committee is scheduled to deliberate on the issue.

The meeting is to decide on granting market authorisation to SII's Covid-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin. Prakash Kumar Singh, director of government and regulatory affairs at the Serum Institute of India (SII), had written a letter to the Drugs Controller General of India (DCGI) recently for the approval to Covovax as a heterologous booster dose for adults in view of the escalating pandemic situation in some countries, sources said.